# Lecia V. Sequist

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lecia-v-sequist/

## Facts

| Field | Value |
| --- | --- |
| Citations | 78,105 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 119 |
| i10-index | 331 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5075333926 |
| ORCID iD | 0000-0002-8965-6991 |
| Works | 816 |

## Researcher papers

Showing 12 of 44.

- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors](https://scholariq.org/papers/genotypic-and-histological-evolution-of-lung-cancers-acquiring-resistance-to/)
- [Isolation of rare circulating tumour cells in cancer patients by microchip technology](https://scholariq.org/papers/isolation-of-rare-circulating-tumour-cells-in-cancer-patients-by-microchip/)
- [Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations](https://scholariq.org/papers/phase-iii-study-of-afatinib-or-cisplatin-plus-pemetrexed-in-patients-with/)
- [Lung cancer](https://scholariq.org/papers/lung-cancer-2/)
- [Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition](https://scholariq.org/papers/circulating-breast-tumor-cells-exhibit-dynamic-changes-in-epithelial-and/)
- [Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs](https://scholariq.org/papers/using-multiplexed-assays-of-oncogenic-drivers-in-lung-cancers-to-select-targeted/)
- [Isolation of circulating tumor cells using a microvortex-generating herringbone-chip](https://scholariq.org/papers/isolation-of-circulating-tumor-cells-using-a-microvortex-generating-herringbone/)
- [Detection of Mutations in <i>EGFR</i> in Circulating Lung-Cancer Cells](https://scholariq.org/papers/detection-of-mutations-in-i-egfr-i-in-circulating-lung-cancer-cells/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers](https://scholariq.org/papers/mechanisms-of-acquired-crizotinib-resistance-in-alk-rearranged-lung-cancers/)
- [<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis](https://scholariq.org/papers/i-egfr-i-mutations-and-i-alk-i-rearrangements-are-associated-with-low-response/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.